Targeting B Cells
B-cell targeted therapies have dominated drug development endeavors owing to the role of B lymphocytes in the pathogenesis of SLE and the regulatory approval of belimumab. Although various strategies have been conceived, the general tactic has been to affect qualitative and/or quantitative changes in B cells.[2] Key trials are illustrated in Table 1.
Curr Opin Rheumatol. 2016;28(5):477-487. © 2016 Lippincott Williams & Wilkins
Comments